Pancreatic neuroendocrine neoplasm
MONDO:0005815A neoplasm with neuroendocrine differentiation that arises from the pancreas. It includes neuroendocrine tumors (low and intermediate grade) and neuroendocrine carcinomas (high grade).
Also known as: PNEN, endocrine pancreas neoplasm, endocrine pancreas neoplasm (disease), endocrine pancreas tumor, endocrine pancreas tumour, neoplasm of endocrine pancreas, pancreatic NEN, pancreatic endocrine neoplasm
1556 clinical trials for this condition and its sub-types, 9 tagged with Pancreatic neuroendocrine neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Pancreatic neuroendocrine neoplasm
-
Pancreatic neuroendocrine tumor 60 trials · 77 incl. sub-types
11 sub-types
- Functional pancreatic neuroendocrine tumor 1 trial · 14 incl. sub-types Sub-types →
- Pancreatic insulin-producing neuroendocrine tumor 0 trials · 13 incl. sub-types Sub-types →
- Somatostatinoma 6 trials
- Pancreatic neuroendocrine tumor G1 1 trial · 5 incl. sub-types Sub-types →
- Non-functional pancreatic neuroendocrine tumor 4 trials Sub-types →
- Glucagonoma 2 trials
- Pancreatic gastrin-producing neuroendocrine tumor 2 trials Sub-types →
- PPoma 1 trial
- VIPoma 1 trial Sub-types →
- GRFoma 0 trials
- Pancreatic delta cell neuroendocrine tumor 0 trials Sub-types →
-
Pancreatic endocrine carcinoma 12 trials
2 sub-types
Most studied deeper sub-types
-
New Vaccine-Chemo combo shows promise for Tough-to-Treat tumors
Disease control PausedThis study tests whether adding a vaccine called SurVaxM to the chemotherapy drug temozolomide can help control advanced neuroendocrine tumors that are growing. About 60 adults with these rare cancers will receive either the combination or chemo alone. The goal is to see if the v…
Phase 2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug shows promise in slowing advanced neuroendocrine tumors
Disease control OngoingThis study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a liver artery shot make cancer treatment more effective?
Disease control OngoingThis early study tests whether giving the drug Lutathera directly into the liver artery is safe and practical for people with neuroendocrine tumors that have spread mainly to the liver. Ten participants will receive two doses into the liver artery followed by two standard IV dose…
Early phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC